Montelukast Krka

Montelukast, the active ingredient in Montelukast Krka, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is employed to prevent asthma symptoms and to relieve allergic rhinitis in adults and children, and is prescribed by healthcare professionals.

GNH USA supplies Montelukast Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and regulatory requirements across EU markets.

Montelukast is a leukotriene receptor antagonist used in the management of respiratory allergic conditions.

Asthma prophylaxis: reduces the frequency of asthma attacks and improves control in patients with persistent asthma. Allergic rhinitis: alleviates nasal congestion, sneezing and itching associated with seasonal or perennial allergic rhinitis. Exercise‑induced bronchoconstriction: prevents bronchospasm triggered by physical activity in susceptible individuals.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate pain often resolving without intervention. - Abdominal pain: discomfort in the stomach region, usually transient. - Nausea: feeling of queasiness that may or may not lead to vomiting. - Cough: occasional irritation of the throat. - Dizziness: brief episodes of light‑headedness. - Fatigue: feeling unusually tired.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue, or throat requiring urgent care. - Stevens‑Johnson syndrome: severe skin reaction with blistering and mucosal involvement. - Eosinophilic granulomatosis with polyangiitis: rare vasculitis affecting multiple organs. - Neuropsychiatric events: mood changes, depression, or suicidal thoughts. - Hepatic injury: signs of liver dysfunction such as jaundice. - Anaphylaxis: immediate hypersensitivity reaction with respiratory distress.

Before prescribing Montelukast, clinicians should consider several safety aspects.

Assess asthma control before initiating: ensure the patient is on appropriate inhaled therapy. Monitor for neuropsychiatric events: watch for mood changes, depression, or suicidal thoughts. Use caution in patients with hepatic impairment: evaluate liver function and adjust if needed. Avoid use in patients with known hypersensitivity to montelukast or excipients. Pregnancy and lactation: discuss risk/benefit with the prescriber before use. Store at room temperature below 25°C: keep in the original container, protect from moisture and direct sunlight.

Montelukast may interact with several medicines; awareness helps maintain efficacy and safety.

Major Interactions (Avoid): - Ritonavir: can increase montelukast plasma concentrations, raising risk of adverse effects. - Phenobarbital, phenytoin, carbamazepine: strong enzyme inducers that may reduce montelukast effectiveness. - Fluconazole: a CYP2C9 inhibitor that may elevate montelukast levels. - Strong CYP2C9 inhibitors (e.g., fluconazole): avoid concomitant use when possible.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of INR; monitor coagulation parameters. - Theophylline: additive bronchodilator effect; observe clinical response. - Beta‑agonists: no significant pharmacokinetic interaction, but monitor overall asthma control.